Nuance Investments LLC Has $50.88 Million Holdings in Solventum Corporation $SOLV

Nuance Investments LLC decreased its holdings in shares of Solventum Corporation (NYSE:SOLV) by 7.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 642,073 shares of the company’s stock after selling 54,894 shares during the quarter. Solventum makes up about 5.6% of Nuance Investments LLC’s portfolio, making the stock its 6th largest position. Nuance Investments LLC’s holdings in Solventum were worth $50,878,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Assetmark Inc. boosted its stake in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the period. Allworth Financial LP boosted its stake in Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after purchasing an additional 129 shares during the period. Hilltop National Bank boosted its stake in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC boosted its stake in Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares during the period. Finally, BOKF NA boosted its stake in Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares during the period.

Insider Activity

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SOLV. UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Thursday, May 14th. Rothschild & Co Redburn began coverage on Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Piper Sandler reduced their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Wedbush began coverage on Solventum in a research report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Trading Down 1.6%

Shares of SOLV opened at $81.07 on Friday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The stock has a 50 day simple moving average of $70.91 and a 200-day simple moving average of $75.21. The stock has a market cap of $14.04 billion, a PE ratio of 9.93, a PEG ratio of 1.27 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the firm posted $1.34 EPS. Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.